Franken RA et al. Atrial fibrillation in the elderly 99 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 The SOLVD investigators. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-heft Studies. The V-heft VA Cooperative Studies Group. Circulation 1993; 87: (6 Suppl): VI102–VI110. Cobler JL, Williams ME, Greenland P. Thyrotoxicosis in institutionalized elderly Patients with Atrial Fibrillation. Arch Intern Med 1984; 144: 1758–1760. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthy- roidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142: 838–842. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects: The Cardiovascular health study. Am J Cardiol 1994, 74: 236–241. Braunwald E. Shattuck lecture: Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and oppor- tunities. N Engl J Med 1997; 337: 1360–1369. Leonard JJ, Shaver J, Thompson M. Left atrial transport function. Trans Am Clin Climatol Assoc 1981; 92: 133–141. Rahimtoola SH, Ehsani A, Sinno MZ, et al. Left atrial trans- port function in myocardial infarction. Importance of its booster pump function. Am J Med 1975; 59: 686–694. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The framingham heart study. Circulation 1998; 98: 946–952. The solvd investigators studies of left ventricular disfunction effect of enalapril on mortality and the development of heart failure in assymptomatic patientes with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685–691. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stoke. The framingham study. Stroke 1991; 22: 983–988. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The stroke prevention in atrial fibrillation investigators. Ann Intern Med 1992; 116: 1–5. Stollberger C, Chnupa P, Kronik G, et.al. Transesophageal echocardiography to asses embolic risk in patients with atrial fibrillation. Ann Intern Med 1998; 128: 630–638. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864–2870. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272. 26 ACTIVE investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Eng J Med 2009; 360: 2066–2078. 27 Healey J, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk. Stroke 2008; 39: 1482–1486. 28 Ott A, Breteler MM, De Bruyne MC, et al. Atrial fibrillation and dementia in a population based study: The rotterdam study. Stroke 1997; 28: 316–321. 29 Knecht S, Oelschlager C, Duning T, et al. Atrial fibrillation in stroke free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125–2132. 30 Miyasaka Y, Barnes ME, Petersen RC, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007; 28: 1962–1967. 31 Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47–52. 32 Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias—Results of the SOPAT trial. Eur Heart J 2004; 25: 1395–1404. 33 Page RL, Tilsch TW, Conolly SJ, et al. Asymptomatic or “Silent”atrial fibrillation. frequency in untreated patients and patients receiving azimilide. Circulation 2003; 107: 1041–1045. 34 Lanzarotti CJ, Olshansky B. Thromboembolism in chronis atrial flutter: Is the risk underestimated. J Am Coll Cardiol 1997; 30: 1506–1511. 35 Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042–1046. 36 Thomas WJ, Helen P, Daniel L, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471–2477. 37 Alaud-din A, Meterissian S, Lisbona R, et al. Assessment of cardiac function in patients who were morbidly obese. Surgery 1990; 108: 809–818. 38 Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identifica- tion of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905–911. 39 Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of- function mutation in familial atrial fibrillation. Science 2003; 299: 251–254. 40 Lai LP, Su MJ, Yeh HM, et al. Association of the human mink gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. Am Heart J 2002; 144: 485–490. 41 Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501. http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology